Does Dr. Triedman study the effects of HIV on cancer survival?

Yes, he researches how HIV affects survival rates in patients with Hodgkin lymphoma.

What treatments has Dr. Triedman researched?

He has studied the implications of effective HIV treatment on cancer outcomes and the establishment of radiotherapy access for cancer patients.

Is Dr. Triedman's work relevant to patients in low-income countries?

Yes, his research focuses on improving cancer treatment accessibility in low-resource settings like rural Rwanda.

How can Dr. Triedman's findings help HIV patients with cancer?

His work shows that with proper HIV care, patients with both conditions can expect similar survival rates to those without HIV.

What population does Dr. Triedman work with in his studies?

He primarily focuses on patients with HIV, Hodgkin lymphoma, and cancer patients in rural areas of low-income countries.

DR. SCOTT A. TRIEDMAN, M.D.

PROVIDENCE, RI

Research Active

Radiology - Radiation Oncology NPI registered 21+ years 2 publications 2018 – 2022 NPI: 1538162508

Radiology - Radiation Oncology

Neoplasms HIV Infections CD4 Lymphocyte Count Rural Population Delivery of Health Care Hodgkin Disease Uganda Referral and Consultation Botswana Radiotherapy Rwanda

Practice Location

825 N MAIN ST
PROVIDENCE, RI 02904-5707

Phone: (401) 521-9700

What does SCOTT TRIEDMAN research?

Dr. Triedman's research centers on the intersection of HIV and cancer, specifically Hodgkin lymphoma. He investigates how effective HIV treatment impacts the survival rates of patients with Hodgkin lymphoma, aiming to ensure that individuals living with HIV have equal survival chances when diagnosed with cancer. He also explores systemic solutions for cancer treatment in rural settings, such as radiotherapy access in Rwanda, where health resources may be scarce. Combining these two areas, his work seeks to find ways to provide quality cancer care to the most vulnerable populations.

Key findings

In a study of 78 patients with Hodgkin lymphoma, those with HIV had survival rates that were comparable to those without HIV, indicating effective HIV treatment does not worsen cancer outcomes.
In Rwanda, of the 580 cancer patients identified needing radiotherapy, 208 (36%) were referred for treatment, demonstrating a functioning referral system.
Among patients who received radiation therapy, nearly half (49%) were alive and cancer-free by the time the study concluded, showcasing the effectiveness of treatment in a rural setting.

Frequently asked questions

Does Dr. Triedman study the effects of HIV on cancer survival?: Yes, he researches how HIV affects survival rates in patients with Hodgkin lymphoma.
What treatments has Dr. Triedman researched?: He has studied the implications of effective HIV treatment on cancer outcomes and the establishment of radiotherapy access for cancer patients.
Is Dr. Triedman's work relevant to patients in low-income countries?: Yes, his research focuses on improving cancer treatment accessibility in low-resource settings like rural Rwanda.
How can Dr. Triedman's findings help HIV patients with cancer?: His work shows that with proper HIV care, patients with both conditions can expect similar survival rates to those without HIV.
What population does Dr. Triedman work with in his studies?: He primarily focuses on patients with HIV, Hodgkin lymphoma, and cancer patients in rural areas of low-income countries.

Publications in plain English

HIV and Hodgkin Lymphoma Survival: A Prospective Study in Botswana.

2022

JCO global oncology

Moahi K, Ralefala T, Nkele I, Triedman S, Sohani A +5 more

Plain English
This study looked at how HIV affects survival rates for people treated for Hodgkin lymphoma (HL) in Botswana. Researchers found that among 78 patients, 47 had HIV, and their survival rates were comparable to those without HIV, suggesting that effective HIV treatment does not worsen outcomes for HL. This is important because it shows that people living with HIV can have similar survival chances as those without HIV when receiving proper care. Who this helps: Patients with HIV and Hodgkin lymphoma.

PubMed

International Radiotherapy Referrals From Rural Rwanda: Implementation Processes and Early Clinical Outcomes.

2018

Journal of global oncology

Hanappe M, Nicholson LT, Elmore SNC, Fehr AE, Bigirimana JB +10 more

Plain English
This study examined how a cancer referral program in rural Rwanda is working for patients needing radiotherapy, particularly for cervical, head and neck, and rectal cancers from 2012 to 2015. Out of 580 patients identified as needing treatment, 208 (36%) were referred to Uganda for radiotherapy, and among those treated, nearly half (49%) were alive and cancer-free by the time of the study. This is significant because it shows that even in rural areas with limited resources, effective cancer treatment pathways can be established, helping address the massive burden of cancer deaths in low-income countries. Who this helps: This benefits cancer patients in rural Rwanda and similar low-income regions.

PubMed

Frequent Co-Authors

Kaelo Moahi Tlotlo Ralefala Isaac Nkele Aliyah Sohani Zola Musimar Jason Efstathiou Philipe Armand Shahin Lockman Scott Dryden-Peterson Maud Hanappe

Physician data sourced from the NPPES NPI Registry . Publication data from PubMed . Plain-English summaries generated by AI. Not medical advice.